Literature DB >> 14688490

Rationale for combination therapy in the management of hypertension.

Marvin Moser1.   

Abstract

Combination drug therapy in the management of hypertension has been used for many years. Recent recommendations of the Seventh Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and the results of several new multiple-drug trials have focused on using the approach as initial therapy in many hypertensive patients. Results of these long-term outcome trials, as well as short-term and smaller studies, indicate the advantage of multiple-drug therapy in the management of hypertension.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14688490      PMCID: PMC8099253          DOI: 10.1111/j.1524-6175.2003.02668.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  22 in total

1.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

2.  Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).

Authors:  William C Cushman; Charles E Ford; Jeffrey A Cutler; Karen L Margolis; Barry R Davis; Richard H Grimm; Henry R Black; Bruce P Hamilton; Joanne Holland; Chuke Nwachuku; Vasilios Papademetriou; Jeffery Probstfield; Jackson T Wright; Michael H Alderman; Robert J Weiss; Linda Piller; Judy Bettencourt; Sandra M Walsh
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Nov-Dec       Impact factor: 3.738

3.  Low-dose combination therapy in hypertension.

Authors:  M Moser; L M Prisant
Journal:  Am Fam Physician       Date:  1997-10-01       Impact factor: 3.292

Review 4.  Suppositions and speculations--their possible effects on treatment decisions in the management of hypertension.

Authors:  M Moser
Journal:  Am Heart J       Date:  1989-12       Impact factor: 4.749

5.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

6.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

7.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

8.  Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.

Authors: 
Journal:  Lancet       Date:  2001-09-29       Impact factor: 79.321

9.  Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group.

Authors: 
Journal:  JAMA       Date:  1979-12-07       Impact factor: 56.272

10.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

Authors:  E J Lewis; L G Hunsicker; R P Bain; R D Rohde
Journal:  N Engl J Med       Date:  1993-11-11       Impact factor: 91.245

View more
  3 in total

Review 1.  Zofenopril plus hydrochlorothiazide: Combination therapy for the treatment of mild to moderate hypertension.

Authors:  Alberto Zanchetti; Gianfranco Parati; Ettore Malacco
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals.

Authors:  Jan Basile
Journal:  Integr Blood Press Control       Date:  2010-06-21

Review 3.  Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data.

Authors:  Claudio Borghi; Arrigo F G Cicero
Journal:  Vasc Health Risk Manag       Date:  2006
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.